BRAF and melanoma: Finally, we wanted to test, whether BRAF status (BRAF V600E IHC positive or BRAF V600E negative), in combination with clinical features (Breslow ≥ 2mm or <2mm and mitotic count ≥ 1/mm2 or <1/mm2) predicts SNB status and survival in the superficially spreading melanomas.